HomeFAGR • EBR
Fagron NV
€16.62
Jan 13, 6:00:00 PM GMT+1 · EUR · EBR · Disclaimer
StockBE listed security
Previous close
€16.88
Day range
€16.60 - €16.78
Year range
€15.14 - €20.05
Market cap
1.22B EUR
Avg Volume
62.86K
P/E ratio
15.63
Dividend yield
1.26%
Primary exchange
EBR
CDP Climate Change Score
C
Market news
Financials
Income Statement
Revenue
Net income
(EUR)Jun 2024Y/Y change
Revenue
214.67M15.55%
Operating expense
64.58M17.26%
Net income
20.21M22.37%
Net profit margin
9.425.96%
Earnings per share
EBITDA
37.71M18.42%
Effective tax rate
21.39%
Total assets
Total liabilities
(EUR)Jun 2024Y/Y change
Cash and short-term investments
98.26M-17.44%
Total assets
1.05B1.99%
Total liabilities
567.95M-2.78%
Total equity
477.11M
Shares outstanding
72.99M
Price to book
2.60
Return on assets
7.61%
Return on capital
9.35%
Net change in cash
(EUR)Jun 2024Y/Y change
Net income
20.21M22.37%
Cash from operations
20.96M-3.11%
Cash from investing
-21.80M-64.37%
Cash from financing
-16.21M0.37%
Net change in cash
-18.16M-176.76%
Free cash flow
15.04M31.59%
About
Fagron NV is a publicly traded multinational group of companies governed by Belgian law. Its registered office is located in Waregem, Belgium, and its headquarters is located at Rotterdam, Netherlands. Founded as Arseus NV, it was formerly the Professional Health Division of Omega Pharma, and became an independent entity via an IPO on October 5, 2007 and has been listed on Euronext Brussels and Euronext Amsterdam since then. Its share is included in the BEL MID-index and the Amsterdam Small Cap Index. The head office of Fagron is located in Rotterdam. Wikipedia
Founded
1990
Website
Employees
3,647
Discover more
You may be interested in
This list is generated from recent searches, followed securities, and other activity. Learn more

All data and information is provided “as is” for personal informational purposes only, and is not intended to be financial advice nor is it for trading purposes or investment, tax, legal, accounting or other advice. Google is not an investment adviser nor is it a financial adviser and expresses no view, recommendation or opinion with respect to any of the companies included in this list or any securities issued by those companies. Please consult your broker or financial representative to verify pricing before executing any trades. Learn more
People also search for
Search
Clear search
Close search
Google apps
Main menu